Published in Ann Gastroenterol on April 12, 2016
ACT-179811 in Patients With Clostridium Difficile Infection (CDI) | NCT01222702
Bacterial Communities: Interactions to Scale. Front Microbiol (2016) 0.77
An Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing. J Clin Microbiol (2017) 0.75
Clostridium difficile bacteremia: Report of two cases in French hospitals and comprehensive review of the literature. IDCases (2017) 0.75
Bezlotoxumab. Hosp Pharm (2017) 0.75
Next-generation probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect Immun (2017) 0.75
Nonantimicrobial drug targets for Clostridium difficile infections. Future Microbiol (2017) 0.75
Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model. Front Microbiol (2017) 0.75
Genome characterization of a novel binary toxin-positive strain of Clostridium difficile and comparison with the epidemic 027 and 078 strains. Gut Pathog (2017) 0.75
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet (2005) 12.54
Clostridium difficile--more difficult than ever. N Engl J Med (2008) 12.12
Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med (2011) 10.29
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol (2013) 7.81
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis (2006) 7.64
Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med (2010) 7.37
Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol (2007) 5.37
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol (2006) 4.87
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (2001) 4.59
Clostridium difficile infection. N Engl J Med (2015) 4.56
Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol (2010) 4.52
Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol (2012) 3.84
Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol (2011) 3.81
Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA (2014) 3.66
Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA (2015) 3.57
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect (2014) 3.33
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol (2002) 3.24
Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg (2007) 3.08
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
Using probiotics and prebiotics to improve gut health. Drug Discov Today (2003) 2.66
Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA (2015) 2.45
Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect (2012) 2.31
Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis (2002) 2.09
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review. Ann Intern Med (2015) 2.02
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis (2011) 1.79
Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother (2013) 1.69
Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg (2011) 1.68
Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol (2000) 1.63
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology (2005) 1.62
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
A cluster of fulminant Clostridium difficile colitis in an intensive care unit in Italy. Infection (2014) 1.55
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother (2013) 1.47
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis (2012) 1.47
Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis (2012) 1.42
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother (2011) 1.39
Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother (2013) 1.38
Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev (2008) 1.35
Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol (2007) 1.33
Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One (2013) 1.24
Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis (2011) 1.23
Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J (1978) 1.21
Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J (2014) 1.19
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis (2009) 1.15
Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun (2001) 1.15
Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut (2004) 1.14
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother (2014) 1.09
Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun (2013) 1.08
Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol (2012) 1.07
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol (2007) 1.05
Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther (2012) 1.02
Pseudomembranous colitis in children. J Gastroenterol Hepatol (2005) 1.00
Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog (2009) 0.99
Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol (2006) 0.97
Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother (2011) 0.93
Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection (2012) 0.92
Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum (2001) 0.91
Pathway to Prevention of Nosocomial Clostridium difficile Infection. Clin Infect Dis (2015) 0.91
Two case reports of Clostridium difficile bacteremia, one with the epidemic NAP-1 strain. Infection (2011) 0.89
Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol (2013) 0.89
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother (2015) 0.88
Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther (2006) 0.86
Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem (2015) 0.86
WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg (2015) 0.85
Pseudomembranous colitis due to Salmonella enterica serotype infantis. Endoscopy (2006) 0.83
Impact of polymerase chain reaction testing on Clostridium difficile infection rates in an acute health care facility. Am J Infect Control (2015) 0.79
Cadazolid: A new hope in the treatment of Clostridium difficile infection. Australas Med J (2015) 0.78
Fecal microbiota transplantation: current clinical efficacy and future prospects. Clin Exp Gastroenterol (2015) 0.77
Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg (2014) 0.77
Factors Predicting Recurrence of Clostridium difficile Infection (CDI) in Hospitalized Patients: Retrospective Study of More Than 2000 Patients. J Investig Med (2015) 0.76
Diagnosis and management of Clostridium difficile infection. Semin Respir Crit Care Med (2015) 0.76
CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease? Can J Surg (2014) 0.76